

## Recommending treatments for the lung cancer patients

Summarize your data from all parts of this lesson, by putting a ✓ in the box if the patient has a mutant version of the gene, and an ✗ if patient does not have a mutant version.

	Patient #1	Patient #2	Patient #3
<b>KRAS mutation</b>			
<b>Rearrangement of Gene A &amp; Gene B</b>			
<b>EGFR mutation</b>			

Below are shown data on the response rates of patients containing different mutations, to different anti-cancer drugs:

	Response Rates		
	erlotinib	crizotinib	carboplatin/paclitaxel (chemotherapy)
KRAS mutation	3%	n/a	23%
Rearrangement of Gene A & Gene B	n/a	56%	29%*
EGFR mutation	77%	n/a	37%

n/a = data are not available for these mutation/drug combinations

\* = includes patients from all categories

Based on the data that you have gathered so far, and the data on the response rates in the table above... Which treatment would you choose for each patient?

Patient #1:

Patient #2:

Patient #3:

Data adapted from Jänne et al., *Clin Cancer Res.* 2006; Jackman et al., *Clin Cancer Res.* 2009; Shaw et al., *Nat Rev Drug Disc.* 2011; Mok et al., *New Eng J Med.* 2009; Eberhard et al., *J Clin Oncol* 2005; Vittorio et al., *J Clin Oncol* 2008.